---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-004158"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:24:34.193341+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Glucotrack receives USPTO approval for three CBGM patents

## Summary
- Three US patents issued by USPTO: US 12,453,494 (Oct 28, 2025), US 12,458,257 and US 12,458,258 (Nov 4, 2025).
- Patents protect proprietary sensor chemistry, intravascular lead design, and low-power electronics for the CBGM platform.
- The patents strengthen Glucotrack's competitive position and IP protection as it advances its implantable CBGM toward commercialization.
- Glucotrack's CBGM is a long-term implantable device with up to 3-year sensor longevity, no wearable component, and direct blood glucose measurement.
- The system measures glucose from blood, aiming to provide real-time readings with less lag than interstitial fluid sensors.

## SEC filing metadata
- accession: 0001493152-26-004158
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315226004158/0001493152-26-004158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315226004158/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-004158
- JSON: https://secwatch.observer/filing/0001493152-26-004158.json
- Plain text: https://secwatch.observer/filing/0001493152-26-004158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.